CIK 0001566044 · Non-accelerated filer<br>Smaller reporting company
Yarrow Bioscience, Inc.
Sign in to watch- Ticker
- YARW
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 453757789
- Phone
- (203) 433-7577
- Business address
- 470 JAMES STREET, SUITE 007, NEW HAVEN, CT, 06513
- Former names
- VYNE Therapeutics Inc., Menlo Therapeutics Inc., Menlo Therapeutics, Inc., Tigercat Pharma, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-03-31 | Zeronda Tyler CHIEF FINANCIAL OFFICER | Shares withheld for taxes | −8,399 | $1.58 | $13K | 118,493 |
| 2025-03-31 | Stuart Iain CHIEF SCIENTIFIC OFFICER | Shares withheld for taxes | −6,044 | $1.58 | $10K | 122,593 |
| 2025-03-31 | Harsch Mutya CHIEF LEGAL OFFICER AND GC | Shares withheld for taxes | −8,828 | $1.58 | $14K | 135,501 |
| 2025-03-31 | Domzalski David PRESIDENT AND CEO | Shares withheld for taxes | −30,498 | $1.58 | $48K | 445,563 |
| 2025-01-21 | Zeronda Tyler CHIEF FINANCIAL OFFICER | Grant or award · Stock Option (right to buy) | +230,000 | 230,000 | ||
| 2025-01-21 | Stuart Iain CHIEF SCIENTIFIC OFFICER | Grant or award · Stock Option (right to buy) | +230,000 | 230,000 | ||
| 2025-01-21 | Harsch Mutya CHIEF LEGAL OFFICER AND GC | Grant or award · Stock Option (right to buy) | +230,000 | 230,000 | ||
| 2025-01-21 | Domzalski David PRESIDENT AND CEO | Grant or award · Stock Option (right to buy) | +730,000 | 730,000 | ||
| 2025-01-15 | LEPORE PATRICK G Director | Purchase | +15,000 | $2.92 | $44K | 51,472 |
| 2024-12-31 | Zeronda Tyler CHIEF FINANCIAL OFFICER | Shares withheld for taxes | −4,675 | $3.35 | $16K | 126,892 |
| 2024-12-31 | Stuart Iain CHIEF SCIENTIFIC OFFICER | Shares withheld for taxes | −4,857 | $3.35 | $16K | 128,637 |
| 2024-12-31 | Harsch Mutya CHIEF LEGAL OFFICER AND GC | Shares withheld for taxes | −4,697 | $3.35 | $16K | 144,329 |
| 2024-12-31 | Domzalski David PRESIDENT AND CEO | Shares withheld for taxes | −24,536 | $3.35 | $82K | 476,061 |
| 2024-12-12 | Borowski Christine Director | Grant or award · Stock Option (right to buy) | +20,000 | 20,000 | ||
| 2024-12-12 | LEPORE PATRICK G Director | Grant or award · Stock Option (right to buy) | +20,000 | 20,000 | ||
| 2024-12-12 | BARBARI SHARON Director | Grant or award · Stock Option (right to buy) | +20,000 | 20,000 | ||
| 2024-12-12 | Basta Steven L Director | Grant or award · Stock Option (right to buy) | +20,000 | 20,000 | ||
| 2024-12-12 | Sandoval Elisabeth Director | Grant or award · Stock Option (right to buy) | +20,000 | 20,000 | ||
| 2024-12-12 | Bruno Anthony D Director | Grant or award · Stock Option (right to buy) | +20,000 | 20,000 | ||
| 2024-11-30 | Domzalski David PRESIDENT AND CEO | Grant or award | +3,901 | $2.10 | $8K | 500,597 |
Page 3 of 6 · 113 trades